Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC) | Zendy

Ricardo Yamada | Zendy; Beatriz Bassaco | Zendy; Stephen Bracewell | Zendy; Kirkpatrick Gillen | Zendy; Madison Kocher | Zendy; Heather Collins | Zendy; Mike B. Anderson | Zendy; Marcelo Guimarães | Zendy

Open Access

Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC)

Author(s) -

Ricardo Yamada,

Beatriz Bassaco,

Stephen Bracewell,

Kirkpatrick Gillen,

Madison Kocher,

Heather Collins,

Mike B. Anderson,

Marcelo Guimarães

Publication year - 2019

Publication title -

journal of gastrointestinal oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.084

H-Index - 39

eISSN - 2219-679X

pISSN - 2078-6891

DOI - 10.21037/jgo.2019.01.01

Subject(s) - medicine , hepatocellular carcinoma , lipiodol , response evaluation criteria in solid tumors , hazard ratio , gastroenterology , proportional hazards model , progressive disease , confidence interval , retrospective cohort study , mitomycin c , surgery , chemotherapy

Conventional transarterial chemoembolization (c-TACE) is a common treatment for unresectable hepatocellular carcinoma (HCC). It is associated with increased overall survival (OS) when compared to conservative management. The purpose of this study is to analyze all c-TACE with mitomycin in patients with HCC at a single institution to determine safety, efficacy, and prognostic factors in a long-term follow-up.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research